Ralph Henry, a researcher at the University of Arkansas and co-founder of Innovate Arkansas client firm InterveXion Therapeutics, will be one of five UA innovators at the third-annual Southeastern Conference Symposium.
IA client InterVexion Therapeutics is developing drug therapies that can help methamphetamine drug abusers break their addiction, and recently it received federal grants totaling $14.5 million to help further its research.
UAMS BioVentures startup and IA client firm InterveXion Therapeutics has been awarded federal grants totaling $14.5 million to further develop its drug therapies that can help methamphetamine drug abusers break their addiction.
